Table I.
Retrospective studies with regard to TC.
| First author (ref.) | Year | No. of patients | Percentage of platinum-sensitive patients | DFSa (months) | DFSb (months) | Major complication rate (%) | Operative mortality (%) | Complete tumor resection rate (%) | Independent factors associated with survival | Median tumor size (cm) | Multiple site recurrence rate (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Leitao et al(10) | 2004 | 26 | 42 | 36 | 10 | 8 | 0 | 53 | Optimal TC and TFI | 5 | 57 |
| Karam et al(13) | 2007 | 47 | 0 | 24 | 16 | 14 | 0 | 64 | Presence of diffuse peritoneal disease | 5 | NA |
| Gultekin et al(14) | 2008 | 20 | 0 | 32 | 6 | 0 | 0 | 35 | - | 4 | 50 |
| Shih et al(11) | 2010 | 77 | 28 | 60 | 13 | 13 | 0 | 72 | Extent of debulking | 5 | 62 |
| Fotopoulou et al(12) | 2011 | 135 | 19 | 37 | 7 | 20 | 5.8 | 39 | Complete tumor resection, interval to primary diagnosis >3 years and serous papillary histology | NA | 85 |
| Hizli et al(17) | 2012 | 23 | 0 | NA | NA | 4 | 0 | 65 | Complete tumor resection | 4 | 83 |
| Fotopoulou et al(18) | 2013 | 406 | 38 | 49c | 12c | 26 | 3.2 | 54 | High-grade histology, tumor residuals at 2nd and 3rd surgery, interval to second relapse, ascites, upper abdominal involvement, distant metastases and non-platinum third-line chemotherapy | NA | NA |
a
In optimally-debulked (no visible tumor) patients;
b
in suboptimally-debulked patients;
c
overall survival, instead of disease-free survival (DFS).
TC, tertiary cytoreduction; TFI, treatment-free interval; NA, not available.